Sionna Therapeutics, Inc.
SION
NASDAQ·Healthcare·Biotechnology·Mkt cap $330.0M
$6.75
▼ -7.66%
P/E
-3.10
Mkt Cap
$330.0M
52-Wk Range
$4.01–$54.97
52-Week Range
$4.01 - $54.97
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 70.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Specialized focus on CFTR function normalization with differentiated mechanisms
- Access to proprietary research and development capabilities in rare genetic diseases
- Potential to address patient populations with limited or no current treatment options
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expansion of cystic fibrosis treatment options and market penetration
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-80.1% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying SION right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 6, 2026
Reported EPS of -$0.66 vs -$0.65 consensus (-1.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
10 analysts · 30% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
30%
Hold
70%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 10, 2026
vs Industry
How SION stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related